Beta 1 -Adrenoceptor Polymorphism Predicts Flecainide Action in Patients with Atrial Fibrillation

Amir M. Nia, Evren Caglayan, Natig Gassanov et al. · 2010

Read Beta 1 -Adrenoceptor Polymorphism Predicts Flecainide Action in Patients with Atrial Fibrillation by Amir M. Nia, Evren Caglayan, Natig Gassanov et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0011421.txt.

Description

Amir Nia and co-authors showed in 2010 that a gene variant can predict how well a heart rhythm drug works. Flecainide steadies the heart in atrial fibrillation, a common rhythm disorder, yet patients respond unevenly for reasons doctors could not see. The team tested whether variation in the gene for a heart adrenaline receptor explained the difference.

Patients carrying a particular form of the receptor gene responded to the drug differently from those without it. A simple genetic test could therefore help doctors choose who should get this drug and who should try another first. That is the promise of personalized prescribing: less trial and error with drugs that carry real side effects. The study is a step toward heart care in which the prescription is matched to the patient's genes from the start.

Catalog record

CREATORAmir M. Nia, Evren Caglayan, Natig Gassanov et al.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE27 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0011421

Browse the full library · About the Tower of Babel